Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorinostat - Merck & Co

Drug Profile

Vorinostat - Merck & Co

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 20 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University; Memorial Sloan-Kettering Cancer Center
  • Developer Banyu; Bayer; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; H. Lee Moffitt Cancer Center and Research Institute; Indiana University; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Center for Tumor Diseases; Roswell Park Cancer Institute; Stanford University; Takeda; University Hospital Heidelberg; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Mesothelioma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Phase II Acute myeloid leukaemia; B-cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I/II Leukaemia; Lymphoma; Solid tumours
  • Phase I Glioblastoma; Gliosarcoma
  • No development reported Brain metastases; Colorectal cancer; Hodgkin's disease
  • Discontinued Gynaecological cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia

Most Recent Events

  • 29 May 2020 Efficacy and adverse events data from a phase I/II trial in Non small cell lung cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 09 Apr 2019 Merck & Co and the Peter Doherty Institute for Infection and Immunity terminates the phase I/II DIVA trial in HIV-1 infections in Australia due to greater risk was involved in evaluation of the hypothesis in the patients than originally anticipated (NCT03198559)
  • 08 Feb 2019 Merck & Co completes a phase II trial in B-cell lymphoma in South-East Asia (PO) (NCT00875056)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top